General Information of Drug Therapeutic Target (DTT) (ID: TTGWKQJ)

DTT Name Rho-associated protein kinase 2 (ROCK2)
Synonyms p164 ROCK-2; Rho-associated, coiled-coil-containing protein kinase II; Rho-associated, coiled-coil-containing protein kinase 2; Rho kinase 2; ROCK-II; KIAA0619
Gene Name ROCK2
DTT Type
Clinical trial target
[1]
BioChemical Class
Kinase
UniProt ID
ROCK2_HUMAN
TTD ID
T06093
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.7.11.1
Sequence
MSRPPPTGKMPGAPETAPGDGAGASRQRKLEALIRDPRSPINVESLLDGLNSLVLDLDFP
ALRKNKNIDNFLNRYEKIVKKIRGLQMKAEDYDVVKVIGRGAFGEVQLVRHKASQKVYAM
KLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNL
MSNYDVPEKWAKFYTAEVVLALDAIHSMGLIHRDVKPDNMLLDKHGHLKLADFGTCMKMD
ETGMVHCDTAVGTPDYISPEVLKSQGGDGFYGRECDWWSVGVFLYEMLVGDTPFYADSLV
GTYSKIMDHKNSLCFPEDAEISKHAKNLICAFLTDREVRLGRNGVEEIRQHPFFKNDQWH
WDNIRETAAPVVPELSSDIDSSNFDDIEDDKGDVETFPIPKAFVGNQLPFIGFTYYRENL
LLSDSPSCRETDSIQSRKNEESQEIQKKLYTLEEHLSNEMQAKEELEQKCKSVNTRLEKT
AKELEEEITLRKSVESALRQLEREKALLQHKNAEYQRKADHEADKKRNLENDVNSLKDQL
EDLKKRNQNSQISTEKVNQLQRQLDETNALLRTESDTAARLRKTQAESSKQIQQLESNNR
DLQDKNCLLETAKLKLEKEFINLQSALESERRDRTHGSEIINDLQGRICGLEEDLKNGKI
LLAKVELEKRQLQERFTDLEKEKSNMEIDMTYQLKVIQQSLEQEEAEHKATKARLADKNK
IYESIEEAKSEAMKEMEKKLLEERTLKQKVENLLLEAEKRCSLLDCDLKQSQQKINELLK
QKDVLNEDVRNLTLKIEQETQKRCLTQNDLKMQTQQVNTLKMSEKQLKQENNHLMEMKMN
LEKQNAELRKERQDADGQMKELQDQLEAEQYFSTLYKTQVRELKEECEEKTKLGKELQQK
KQELQDERDSLAAQLEITLTKADSEQLARSIAEEQYSDLEKEKIMKELEIKEMMARHKQE
LTEKDATIASLEETNRTLTSDVANLANEKEELNNKLKDVQEQLSRLKDEEISAAAIKAQF
EKQLLTERTLKTQAVNKLAEIMNRKEPVKRGNDTDVRRKEKENRKLHMELKSEREKLTQQ
MIKYQKELNEMQAQIAEESQIRIELQMTLDSKDSDIEQLRSQLQALHIGLDSSSIGSGPG
DAEADDGFPESRLEGWLSLPVRNNTKKFGWVKKYVIVSSKKILFYDSEQDKEQSNPYMVL
DIDKLFHVRPVTQTDVYRADAKEIPRIFQILYANEGESKKEQEFPVEPVGEKSNYICHKG
HEFIPTLYHFPTNCEACMKPLWHMFKPPPALECRRCHIKCHKDHMDKKEEIIAPCKVYYD
ISTAKNLLLLANSTEEQQKWVSRLVKKIPKKPPAPDPFARSSPRTSMKIQQNQSIRRPSR
QLAPNKPS
Function
Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation. Protein kinase which is a key regulator of actin cytoskeleton and cell polarity.
KEGG Pathway
cGMP-PKG signaling pathway (hsa04022 )
cAMP signaling pathway (hsa04024 )
Chemokine signaling pathway (hsa04062 )
Sphingolipid signaling pathway (hsa04071 )
Vascular smooth muscle contraction (hsa04270 )
Wnt signaling pathway (hsa04310 )
Axon guidance (hsa04360 )
Focal adhesion (hsa04510 )
Platelet activation (hsa04611 )
Leukocyte transendothelial migration (hsa04670 )
Regulation of actin cytoskeleton (hsa04810 )
Oxytocin signaling pathway (hsa04921 )
Pathogenic Escherichia coli infection (hsa05130 )
Shigellosis (hsa05131 )
Salmonella infection (hsa05132 )
Pathways in cancer (hsa05200 )
Proteoglycans in cancer (hsa05205 )
Reactome Pathway
EPHA-mediated growth cone collapse (R-HSA-3928663 )
G alpha (12/13) signalling events (R-HSA-416482 )
Sema4D induced cell migration and growth-cone collapse (R-HSA-416572 )
VEGFA-VEGFR2 Pathway (R-HSA-4420097 )
RHO GTPases Activate ROCKs (R-HSA-5627117 )
EPHB-mediated forward signaling (R-HSA-3928662 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Belumosudil DM548TK Graft-versus-host disease 4B24 Approved [1]
------------------------------------------------------------------------------------
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [2]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [3]
------------------------------------------------------------------------------------
13 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indazolyl-thiadiazolamine derivative 1 DMR2GW1 N. A. N. A. Patented [4]
PMID28048944-Compound-11 DMQ6WEN N. A. N. A. Patented [4]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [4]
PMID28048944-Compound-2 DM9ZXOP N. A. N. A. Patented [4]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [4]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [4]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [4]
PMID28048944-Compound-6 DM5RCBV N. A. N. A. Patented [4]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [4]
Tricyclic compound 4 DMEIG16 N. A. N. A. Patented [4]
Tricyclic compound 5 DMLPMS7 N. A. N. A. Patented [4]
Tricyclic compound 6 DMMJ81G N. A. N. A. Patented [4]
Tricyclic compound 7 DME84S5 N. A. N. A. Patented [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Patented Agent(s)
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CDE-5110 DMGQ9WP Inflammation 1A00-CA43.1 Terminated [5]
------------------------------------------------------------------------------------
9 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMA-237 DMW9TRD Chronic obstructive pulmonary disease CA22 Investigative [6]
ATS-907 DMHEK4U Glaucoma/ocular hypertension 9C61 Investigative [6]
Glycyl-H 1152 DM0SCK8 Discovery agent N.A. Investigative [7]
PMID20462760C22 DMQFKBI Discovery agent N.A. Investigative [8]
PMID20471253C32 DMBQAKO Discovery agent N.A. Investigative [9]
PMID20684608C35 DMVUEZI Discovery agent N.A. Investigative [10]
RKI-1447 DMGTAWC Discovery agent N.A. Investigative [11]
SR-3850 DM3Y09Z Solid tumour/cancer 2A00-2F9Z Investigative [6]
TRN-101 DMXNSTF Chronic obstructive pulmonary disease CA22 Investigative [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Chronic obstructive pulmonary disease CA23 Lung tissue 8.76E-01 6.89E-03 0.03
Chronic obstructive pulmonary disease CA23 Small airway epithelium 1.39E-02 -0.09 -0.39
Rheumatoid arthritis FA20 Synovial tissue 1.55E-01 0.12 0.71
------------------------------------------------------------------------------------

References

1 Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
4 Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025959)
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504).
7 Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52.
8 Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9.
9 Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9.
10 Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37.
11 Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.